First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
PF-06753512（一种基于疫苗的免疫疗法方案 (VBIR)）在非转移性激素敏感性生化复发和转移性去势抵抗性前列腺癌 (mCRPC) 中的首次人体 1 期研究
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2022-005702
Autio, Karen A; Higano, Celestia S; Nordquist, Luke; Appleman, Leonard J; Zhang, Tian; Zhu, Xin-Hua; Babiker, Hani; Vogelzang, Nicholas J; Prasad, Sandip M; Schweizer, Michael T; Madan, Ravi A; Billotte, Stephane; Cavazos, Nora; Bogg, Orlaith; Li, Ray; Chan, Kam; Cho, Helen; Kaneda, Megan; Wang, I-Ming; Zheng, Jenny; Tang, Szu-Yu; Hollingsworth, Robert; Kern, Kenneth A; Petrylak, Daniel P
